Fintel reports that on August 7, 2023, UBS upgraded their outlook for DaVita (NYSE:DVA) from Neutral to Buy .
Analyst Price Forecast Suggests 2.11% Downside
As of August 2, 2023, the average one-year price target for DaVita is 106.52. The forecasts range from a low of 96.96 to a high of $120.75. The average price target represents a decrease of 2.11% from its latest reported closing price of 108.81.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for DaVita is 11,824MM, an increase of 0.73%. The projected annual non-GAAP EPS is 6.76.
What is the Fund Sentiment?
There are 985 funds or institutions reporting positions in DaVita. This is a decrease of 28 owner(s) or 2.76% in the last quarter. Average portfolio weight of all funds dedicated to DVA is 0.10%, an increase of 0.63%. Total shares owned by institutions decreased in the last three months by 2.75% to 79,313K shares. 
The put/call ratio of DVA is 3.12, indicating a bearish outlook.
What are Other Shareholders Doing?
Berkshire Hathaway holds 36,096K shares representing 39.82% ownership of the company. No change in the last quarter.
Lsv Asset Management holds 1,875K shares representing 2.07% ownership of the company. In it's prior filing, the firm reported owning 1,943K shares, representing a decrease of 3.65%. The firm increased its portfolio allocation in DVA by 17.48% over the last quarter.
Invesco holds 1,643K shares representing 1.81% ownership of the company. In it's prior filing, the firm reported owning 1,842K shares, representing a decrease of 12.14%. The firm decreased its portfolio allocation in DVA by 7.75% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,544K shares representing 1.70% ownership of the company. In it's prior filing, the firm reported owning 1,520K shares, representing an increase of 1.53%. The firm increased its portfolio allocation in DVA by 1.86% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,301K shares representing 1.44% ownership of the company. In it's prior filing, the firm reported owning 639K shares, representing an increase of 50.92%. The firm increased its portfolio allocation in DVA by 112.43% over the last quarter.
DaVita Background Information
(This description is provided by the company.)
DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.
Additional reading:
- DaVita Inc. 2nd Quarter 2023 Results
- AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
- DaVita Inc. 1st Quarter 2023 Results
- DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan
- DaVita Inc. Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
